Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 13/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5372964 | 1.00 | CCR3 (0.62) | CCR3NPC1RAB9AEPHX2PYGL | |
| SCHEMBL5378357 | 0.93 | CCR3 (0.54) | CCR3NPC1RAB9AEPHX2PYGL | |
| SCHEMBL5383318 | 0.87 | CCR3 (0.47) | CCR3CYP2D6 | |
| SCHEMBL5387413 | 0.87 | CCR3 (0.47) | CCR3CYP2D6 | |
| SCHEMBL5378259 | 0.87 | CCR3 (0.54) | CCR3NPC1RAB9AEPHX2PYGL | |
| SCHEMBL5398666 | 0.87 | CCR3 (0.54) | CCR3NPC1RAB9AEPHX2PYGL | |
| SCHEMBL5393229 | 0.83 | CCR3 (0.45) | CCR3NPC1RAB9AEPHX2PYGL | |
| SCHEMBL5378339 | 0.83 | CCR3 (0.45) | CCR3NPC1RAB9AEPHX2PYGL | |
| SCHEMBL5378235 | 0.81 | CCR3 (0.48) | CCR3CYP2D6 | |
| SCHEMBL5373024 | 0.81 | CCR3 (0.48) | CCR3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | ACKR3, CCL11, GPR17 | CCR3 18/4885NPC1 1208/4885RAB9A 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.